{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:07:31Z","timestamp":1790168851150,"version":"4.1.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>With the annual increase in the incidence and mortality rates of gastric cancer, it has gradually become one of the significant threats to human health. Approximately 90% of gastric cancer patients are diagnosed with adenocarcinoma. Although the 5-year survival rate for early-stage gastric cancer can exceed 90%, due to its concealed symptoms, less than half of the patients are eligible for radical surgical treatment upon diagnosis. For gastric cancer patients receiving palliative treatment, the current expected survival time is only about one year. In China, the majority of gastric cancer patients, accounting for about 80% of the total, are in the locally advanced stage. For these patients, radical surgery remains the primary treatment option; however, surgery alone is often inadequate in controlling tumor progression. In the pivotal MAGIC study, the recurrence rate was as high as 75%, and similar results were obtained in the French ACCORD07-FFCD9703 study. Numerous clinical trials are currently exploring preoperative neoadjuvant therapy for patients with locally advanced gastric cancer. Data indicates that preoperative neoadjuvant therapy can not only reduce the size of the local tumor but also shrink surrounding lymph nodes, thereby downstaging the tumor and improving the R0 resection rate. Additionally, it can decrease tumor cell activity and eliminate potential micrometastases. The emergence of various immunotherapies has ushered in a new era for neoadjuvant treatment options for gastric cancer.<\/jats:p>","DOI":"10.3389\/fonc.2025.1528529","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:13:11Z","timestamp":1744348391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Prospects for the application of pathological response rate in neoadjuvant therapy for gastric cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Zicheng","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v149.4","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Intl J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.2014.40.issue-3","article-title":"Review article: the epidemiology and prevention of gastric cancer","volume":"40","author":"Fock","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1010428317714626","DOI":"10.1177\/1010428317714626","article-title":"Progress in the treatment of advanced gastric cancer","volume":"39","author":"Song","year":"2017","journal-title":"Tumour Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","article-title":"Immune checkpoints and rheumatic diseases: What can cancer immunotherapy teach us","volume":"12","author":"van der Vlist","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i17","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"B\u00f6ger","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/diagnostics11040597","article-title":"High expression of PD-L1 is associated with better survival in pancreatic\/periampullary cancers and correlates with epithelial to mesenchymal transition","volume":"11","author":"Thakur","year":"2021","journal-title":"Diagnostics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: From enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v128.4","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/cc.22135","article-title":"PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A","volume":"11","author":"Patsoukis","year":"2012","journal-title":"Cell Cycle"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7659462","DOI":"10.1155\/2017\/7659462","article-title":"CD80 expressed by CD8+ T cells contributes to PD-L1-induced apoptosis of activated CD8+ T cells","volume":"2017","author":"Rollins","year":"2017","journal-title":"J Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130208","article-title":"Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection","volume":"211","author":"Lu","year":"2014","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signalling molecules for immune modulation","volume":"12","author":"Yao","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.286","article-title":"Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC)","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III checkMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00170","article-title":"Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from checkMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature reviews","volume":"18","author":"Db","year":"2021","journal-title":"Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34296","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis","volume":"152","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1377690","article-title":"First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003984","article-title":"Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis","volume":"10","author":"Xing","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6379-8","article-title":"The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid Malignancies","volume":"25","author":"Keung","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti\u2013PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discovery"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0314","article-title":"The HIF-1\u03b1 hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy","volume":"2","author":"Palaz\u00f3n","year":"2012","journal-title":"Cancer Discovery"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Ea","year":"2019","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Yang","year":"2018","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz019","article-title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: Evidence for an early, on-therapy biomarker of response","volume":"30","author":"Stein","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/1066896919869477","article-title":"Pathological tumor regression grade classifications in gastrointestinal cancers: Role on patients\u2019 Prognosis","volume":"27","author":"Fanelli","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"153538","DOI":"10.1016\/j.prp.2021.153538","article-title":"Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy","volume":"224","author":"L\u00fctken","year":"2021","journal-title":"Pathol - Res Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jso.v122.3","article-title":"Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer","volume":"122","author":"Stark","year":"2020","journal-title":"J Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.06.016","article-title":"Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC)","volume":"71","author":"Nekljudova","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"B48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10120-011-0040-6","article-title":"New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points","volume":"14","author":"Sano","year":"2011","journal-title":"Gastric Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10120-014-0401-z","article-title":"Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A)","volume":"18","author":"Nakamura","year":"2015","journal-title":"Gastric Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E","article-title":"Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy","volume":"49","author":"Rosen","year":"1982","journal-title":"Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0084-3873(08)70249-9","article-title":". Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"2007","author":"Barkin","year":"2007","journal-title":"Yearbook Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3332\/ecancer.2021.1168","article-title":"Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: Impact on pathological complete response and safety","volume":"15","author":"Villanueva","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"B57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1159\/000479154","article-title":"Preoperative capecitabine, oxaliplatin, and irinotecan in resectable gastric or gastroesophageal junction cancer: Pathological response as primary endpoint and FDG-PET predictions","volume":"93","author":"Berenato","year":"2017","journal-title":"Oncology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: A randomized phase II trial of the AIO EGA study group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01286-w","article-title":"A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer","volume":"25","author":"Hasegawa","year":"2022","journal-title":"Gastric Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001468","article-title":"The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicenter Real-world clinical study","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.294","article-title":"Perioperative sintilimab combination with SOX for resectable locally advanced gastric\/gastroesophageal junction cancer(GC\/GEJC): Initial findings of a single-arm phase II trial","volume":"40","author":"Ding","year":"2022","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4003","article-title":"Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK","volume":"40","author":"Al-Batran","year":"2022","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","article-title":"Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: Real-world experience with a consecutive patient cohort","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/JS9.0000000000001119","article-title":"Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.suronc.2019.10.002","article-title":"Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer","volume":"32","author":"Petrioli","year":"2020","journal-title":"Surg Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers16071376","article-title":"Posterior and para-aortic (D2plus) lymphadenectomy after neoadjuvant\/conversion therapy for locally advanced\/oligometastatic gastric cancer","volume":"16","author":"Marrelli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000877","article-title":"Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer","volume":"31","author":"Petrioli","year":"2020","journal-title":"Anticancer Drugs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1528529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:13:12Z","timestamp":1744348392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1528529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":71,"alternative-id":["10.3389\/fonc.2025.1528529"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1528529","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1528529"}}